Screen Reader Access
h






image01

Wahajuddin, Ph.D.

Principal Scientist,Pharmaceutics & Pharmacokinetics

C.D.R.I




Research Interests

Experimental Therapeutics:

Studying pharmacokinetics and biopharmaceutics of potential candidate molecules (synthetic as well as of natural origin) of CSIR-CDRI drug R&D pipeline (in addition to marketed drugs/metabolites/natural products) and deciphering the molecular mechanism(s) of ADME/disposition thereof.

Research Area

Bio-analysis

Bio-analytical method development and validation, as per the regulatory (US-FDA, ICH etc.) guidelines, on HPLC and LC-MS/MS platform for quantitative determination of small molecules (NCEs/Drugs and/or metabolites) in different biological matrices

Pharmacokinetic

Characterization of the in vivo pharmacokinetics (bio-availability, dose-proportionality, gender variation, inter-species comparison) following oral and parenteral routes of administration in animal models. Toxicokinetic and tissue distribution studies to support regulatory toxicology

Metabolism, Metabolite Identification and CYP Phenotyping

In vitro/in vivo Metabolism of new chemical entities and/or drugs using animal models, scaling preclinical and in-vitro data to predict events in humans for preliminary assessment of safe exposure levels, determination of the metabolite profiles of drug candidates using liver microsomes/human recombinant CYP450 isozymes, Identify Phase I or Phase II enzymes responsible for metabolite formation, predict drug interactions due to inhibition or induction of drug metabolizing enzymes.

Interaction

Drug-drug, herb-drug and food-drug interaction studies for suggesting benefits (as potential combination)/risks of the same in therapies.

Biopharmaceutics

Permeability/Absorption Characterization Studies across Parallel Artificial Membrane Permeability Assay (PAMPA) and in situ rat model, Protein Binding and Simulated Gastro-intestinal Stability for new chemical entities/drugs.